Skip to main content

Coronavirus Infections

Epidemiology and severity of pediatric influenza hospitalizations before and during the COVID-19 pandemic: a surveillance study of the Canadian immunization monitoring program (IMPACT), 2012–2023.

Di Chiara C. The Lancet Regional Health – Americas 2026;:https://doi.org/10.1016/j.lana.2026.101525.

Published on 16/6/2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.

Morgan E. The Lancet Oncology 2026;:https://doi.org/10.1016/S1470-2045(26)00089-6.

Published on 16/6/2026
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

Hayden FG. New England Journal of Medicine 2026;394(19):1905-1915.

Published on 15/6/2026
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

Engel JJ. British Journal of Clinical Pharmacology 2026;92(6):1685-1695.

Published on 7/6/2026
Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects.

Zhou ZY. British Journal of Clinical Pharmacology 2026;92(6):1886-1893.

Published on 7/6/2026
Comprehensive longitudinal profiling identifies differential frequency, epitope specificity, and effector function of CD8+ T-cells across COVID-19 disease severities.

Hernandez SPA. eBioMedicine 2026;:https://doi.org/10.1016/j.ebiom.2026.106310.

Published on 27/5/2026
MERS-CoV: travel from the Middle East advice sheet.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026
MERS-CoV: biological principles for the control of MERS-CoV.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026
MERS-CoV: clinical management and guidance.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026
MERS-CoV: background information.

UK Health Security Agency (UKHSA); 2026.

Published on 19/5/2026

1
2
3
4
...